• +1-646-491-9876
    • +91-20-67278686

    Search

    Gastritis Pipeline Review H1 2017

    Gastritis Pipeline Review H1 2017

    • Report Code ID: RW0001799295
    • Category Pharmaceuticals
    • No. of Pages 41
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Gastritis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gastritis - Pipeline Review, H1 2017, provides an overview of the Gastritis (Gastrointestinal) pipeline landscape.

    Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years) . Gastritis can be caused by medications such as ibuprofen, aspirin, naproxen on long periods of consumption, excess intake of alcohol, Helicobacter pylori infection, certain autoimmune disorders, bile reflux, substance abuse (cocaine) , consumption of corrosive or caustic substances such as poisons, extreme stress, viral infections and trauma. The symptoms of gastritis may include loss of appetite, nausea and vomiting, abdominal pain and black stools. Treatment includes use of antacids, Histamine 2 (H2) antagonists and proton pump inhibitors.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Gastritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gastritis (Gastrointestinal) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Gastritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 4 and 2 respectively.

    Gastritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Gastritis (Gastrointestinal) .
    - The pipeline guide reviews pipeline therapeutics for Gastritis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Gastritis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Gastritis (Gastrointestinal) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Gastritis (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Gastritis (Gastrointestinal) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Gastritis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Gastritis - Overview
    Gastritis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Gastritis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Gastritis - Companies Involved in Therapeutics Development
    BCWorld Pharm Co Ltd
    Boryung Pharmaceutical Co Ltd
    Daewon Pharm Co Ltd
    Recce Ltd
    RedHill Biopharma Ltd
    Gastritis - Drug Profiles
    BCWPA-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BGC-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DW-3101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HPi-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    netazepide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ondansetron hydrochloride CR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PMKS-005 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RECCE-327 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gastritis - Dormant Projects
    Gastritis - Product Development Milestones
    Featured News & Press Releases
    Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis
    Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results
    Mar 02, 2015: Positive Bioavailability Studies of RedHill's BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting
    Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis
    Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Gastritis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Gastritis - Pipeline by BCWorld Pharm Co Ltd, H1 2017
    Gastritis - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
    Gastritis - Pipeline by Daewon Pharm Co Ltd, H1 2017
    Gastritis - Pipeline by Recce Ltd, H1 2017
    Gastritis - Pipeline by RedHill Biopharma Ltd, H1 2017
    Gastritis - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Gastritis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    BCWorld Pharm Co Ltd
    Boryung Pharmaceutical Co Ltd
    Daewon Pharm Co Ltd
    Recce Ltd
    RedHill Biopharma Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//gastritis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//gastritis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//gastritis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments